Juno vs Isomorphic Labs
Side-by-side comparison of features, pricing, and ratings
At a glance
| Dimension | Juno | Isomorphic Labs |
|---|---|---|
| Target Users | Chronic illness patients | Pharma companies & research institutions |
| Core Function | Symptom tracking & doctor reports | AI-driven drug discovery |
| Pricing | Freemium | Contact sales |
| AI Methodology | Pattern recognition on user logs | Predictive & generative models (AlphaFold) |
| Partnerships | None (consumer app) | J&J, Novartis |
If you're a patient managing a chronic condition, Juno gives you a freemium AI companion to log symptoms and generate doctor-ready reports. If you're a pharma company needing to accelerate drug discovery, Isomorphic Labs offers deep partnerships leveraging AlphaFold—but it's enterprise-only and priced via contact. Choose based on your role: consumer vs. big pharma.
A 24/7 AI health assistant for chronic illness that logs symptoms by voice or text and turns them into doctor-ready summaries.
Visit Website
Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform.
Visit WebsiteWhat real users say: Juno vs Isomorphic Labs
Not marketing copy and not our opinion — a structured sweep of public discussion (reviews, forums, communities and video comments), showing what people praise and what they complain about for each tool.
Juno
63 mentions across 3 sources · 7% positive — critical (averaged across 3 sources)
Hacker News, App Store, Lemmy
What users praise
- • Good community aspect for chronic illness support.
- • Allows tracking of symptoms, meds, sleep, and mood.
- • Helps some users organize health data for doctor visits.
- • Positive initial experience before hitting paywall.
What frustrates them
- • Unable to cancel subscription or delete account easily.
- • App crashes frequently, especially on iPhone 16 Pro.
- • Chat support doesn't work and robo-responses are useless.
- • Free tier runs out of credits almost immediately.
Researched Jul 3, 2026
Isomorphic Labs
No verifiable community signal. We scanned public discussion on Oct 7, 2026 and found posts matching the name “Isomorphic Labs”, but could not establish that they are about this product rather than something else sharing its name. Rather than publish a score built on the wrong subject, we publish none.
Who should pick which
- Chronic illness patientPick: Juno
Juno offers free symptom tracking, pattern recognition, and doctor report generation—ideal for managing ME/CFS, fibromyalgia, or autoimmune conditions.
- Pharma VP of Drug DiscoveryPick: Isomorphic Labs
Isomorphic Labs provides AI-driven molecular design and simulation via deep partnerships, leveraging AlphaFold to accelerate therapeutic development at scale.
- Researcher without pharma tiesPick: Juno
Isomorphic Labs is not open to individual researchers; Juno's data export can support research on symptom patterns from user logs.
- Startup seeking drug repurposing toolsPick: Isomorphic Labs
Only if you can forge a collaboration; otherwise, Juno is irrelevant. Isomorphic Labs works with established pharma, not startups.
- Patient needing emergency responsePick: Juno
Neither tool suits emergencies, but Juno is the only one that tracks daily health; however, it explicitly does not provide real-time alerts.
Frequently Asked Questions
Juno vs Isomorphic Labs: which should you choose?
If you're a patient managing a chronic condition, Juno gives you a freemium AI companion to log symptoms and generate doctor-ready reports. If you're a pharma company needing to accelerate drug discovery, Isomorphic Labs offers deep partnerships leveraging AlphaFold—but it's enterprise-only and priced via contact. Choose based on your role: consumer vs. big pharma.
Can Juno diagnose my condition?
No. Juno is for tracking symptoms and generating reports for doctors; it does not provide medical advice or diagnosis.
Does Isomorphic Labs sell software licenses?
No. It operates through research collaborations with pharma partners; no API or standalone software is offered.
What is the latest news on Isomorphic Labs?
As of May 2026, it closed a Series B round. In January 2026, it partnered with Johnson & Johnson. It also raised $600M in 2025 and appointed a President and CMO.
Is Juno free?
Juno offers a freemium model; basic tracking and reports are free but premium features may require payment.
Which tool is better for drug discovery?
Isomorphic Labs is purpose-built for drug discovery; Juno is not relevant for that use case.
Can I export my data from Juno?
Yes, Juno allows data export as PDF or CSV.
Who founded Isomorphic Labs?
Sir Demis Hassabis, CEO of DeepMind.
Does Juno integrate with electronic health records?
No, Juno does not integrate with EHR systems.
More Juno or Isomorphic Labs comparisons
These tools are polar opposites in audience and purpose. Ironclaw AI Vision is a free, offline-first PWA for individual fitness tracking with AI coaching and meal planning – ideal for privacy-consciou
Angle and Isomorphic Labs serve completely different domains—Angle is a free, niche pose-measurement tool for fitness professionals, while Isomorphic Labs is an enterprise AI drug discovery platform f
These tools serve completely different markets. CalBye is a consumer nutrition app for individuals wanting effortless calorie tracking via photos, while Isomorphic Labs is an enterprise drug discovery
Choose Ray if you need an adaptive, low-barrier AI personal trainer for flexible, voice-guided workouts — it's ideal for busy individuals wanting consistency without gym intimidation. Choose Isomorphi
MediSphere and Isomorphic Labs serve completely different healthcare verticals. Choose MediSphere if you run a small clinic needing AI-powered administration, no-show prediction, and EHR. Choose Isomo
Isomorphic Labs and Swimio serve completely different worlds: one is a high-stakes pharma AI platform for billion-dollar drug programs, the other a consumer fitness app for swimmers. Choose based on y
Explore each tool further
Browse these categories
One email a week — new tools, honest comparisons, no spam.
Last reviewed: July 3, 2026